Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Medscape

Drop in HIV/HCV Coinfections After Nationwide HCV Program

“Nevertheless, these findings highlight the importance of treatment adherence, regular follow-up, and targeted prevention in order to reach the WHO [World Health Organization] HCV elimination goals,” ...
Medscape

HCV Antiviral Moves Toward EU Use in Acute Infection

A widely used pangenotypic combination therapy has moved closer to European approval for acute hepatitis C virus (HCV) infection, offering clinicians a new option for early-stage treatment across all ...
Health Affairs

To Eliminate HCV Among Persons Who Use Drugs: Embrace The Complexity

If we truly want to eliminate hepatitis C among persons who use drugs, we must also commit to addressing the complex realities of their lived experience. Offering HCV testing at clinical, ...
Healio

Measurements for HCV cure could be done earlier among people who inject drugs

Please provide your email address to receive an email when new articles are posted on . Measurements taken for HCV cure at 4 weeks produced identical results for people who inject drugs as those taken ...
Healio

‘Data are sobering’: Antiviral prescriptions for HCV drop by nearly 66% since 2015

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Annual courses of direct-acting antivirals for HCV have ...